Previous studies identified two mammalian prion protein (PrP) 
, we used prion proteins lacking one or both polybasic domains expressed from Chinese hamster ovary (CHO) cells as substrates in serial protein misfolding cyclic amplification (sPMCA) reactions. After ,5 rounds of sPMCA, PrP Sc molecules lacking the central polybasic domain (DC) were formed. Surprisingly, in contrast to wild-type prions, DC-PrP Sc prions could bind to and induce quantitative conversion of all the polybasic domain mutant substrates into PrP Sc molecules. Remarkably, DC-PrP Sc and other polybasic domain PrP Sc molecules displayed diminished or absent biological infectivity relative to wild-type PrP Sc , despite their ability to seed sPMCA reactions of normal mouse brain homogenate. Thus, DC-PrP Sc prions interact with PrP C molecules through a novel interaction mechanism, yielding an expanded substrate range and highly efficient PrP Sc propagation. Furthermore, polybasic domain deficient PrP Sc molecules provide the first example of dissociation between normal brain homogenate sPMCA seeding ability from biological prion infectivity. These results suggest that the propagation of PrP Sc molecules may not depend on a single stereotypic mechanism, but that normal PrP C
/PrP
Sc interaction through polybasic domains may be required to generate prion infectivity.
Introduction
Prions are infectious proteinaceous particles that cause fatal neurodegenerative diseases, including Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD). Prions contain PrP Sc , a protease-resistant detergent-insoluble b-sheet-rich conformer of the normal cellular protein PrP C [1, 2] . PrP Sc is an essential and possibly the sole component of infectious prions. Prion propagation and disease require the presence of PrP C , encoded by the host Prnp gene [3, 4, 5, 6] .
Cell-free in vitro propagation systems have emerged as valuable tools to investigate PrP Sc and prion propagation [7] . By serial protein misfolding cyclic amplification (sPMCA), prion infectivity can be propagated in vitro [8] . More rapid and less costly than the gold standard inoculation bioassay, sPMCA has been proposed as an in vitro method to detect prion infectivity [9] . Indeed, samples which seed robust sPMCA propagation have been previously associated with biological infectivity [8, 10] . However, it is unknown if PrP Sc molecules that robustly seed PMCA propagation in wild type brain homogenate are always associated with appropriate levels of specific infectivity.
Recent studies have reconstituted infectious PrP Sc propagation using purified PrP C substrate and supplementary conversion cofactors, a set of minimal components that appear necessary for prion propagation [11, 12] . PrP Sc appears to propagate by autocatalysis, binding PrP C to induce conversion into a new PrP Sc molecule [13] . However, the mechanisms of binding and conversion remain unclear. Studies using motif-grafted antibodies or PrP-derived peptides identified two polybasic regions that bind strongly to PrP Sc [14, 15, 16] , suggesting that these PrP C domains may serve as docking sites for PrP Sc . The N-terminal (N-PBD, [23] [24] [25] [26] [27] [28] and central (C-PBD, 100-109) polybasic domains both fall in the Nterminal flexible region of PrP C , which is less ordered than the Cterminus [17, 18] . Antibodies directed at C-PBD can impede prion propagation in cultured cells and in vivo [19, 20] , possibly by blocking a PrP Sc -binding site on PrP C . The polybasic domains may also be involved in interaction with lipid molecules during the conversion process [21] and may affect the structure of misfolded prion protein [22] .
Mice overexpressing PrP transgenes lacking amino acids 23-88 show reduced prion susceptibility [23] , but these studies did not examine N-PBD in isolation. Transgenic mice with deletions that include C-PBD display lethal neurologic illness, but this phenotype precluded inoculation experiments assessing prion susceptibility [24, 25, 26] . The specific role of these domains in the context of the entire PrP C molecule has been studied in N2a cells co-expressing wild-type and mutant PrP C [27] , but biochemical examinations of binding interactions and of propagation with pure substrates are lacking.
In full-length PrP 
Materials and Methods

Mutagenesis and expression of recPrP-myc for binding
Sequence encoding mouse PrP-A 23-230 was amplified, using the following primers to add an N-terminal start codon and a Cterminal tag encoding amino acids 410-419 of human c-myc (NCBI accession number NP_002458.2): N: 59-aaaaaacatatgaaaaagcggccaaagcctggagggt-39, C: 59-aaaactcgagtcattacagatcctcttctgagatgagtttttgttcggatcttctcccgtcgtaatag-39. This fusion gene was inserted into pET22b(+) for bacterial expression. N-terminal (DN, 23-28) and central (DC, 100-109) polybasic domains were deleted by site-directed mutagenesis (GeneTailor, Invitrogen, Carlsbad, CA). From transfected Escherichia coli Rosetta cells, recombinant PrP was purified in a manner similar to that described by Wang et al. [12] . Cells from 500 mL induced (Overnight Express Autoinduction System, Novagen, EMD Chemicals, Gibbstown, NJ) overnight culture were pelleted at 8,0006g for 10 min.; lysed with 40 mL BugBuster, Lysonase (Novagen), and intermittent sonication over 20 min.; and inclusion bodies were prepared by two cycles of centrifugation (16,0006g, 15 min.) and 0.16 Bugbuster resuspension, followed by an additional 16,0006g 15 min. spin. Inclusion body pellets were solubilized in 8 mL 8 M guanidine hydrochloride, insoluble material removed by centrifugation (8,0006g, 10 min.), and protein added to 3.6 g Ni-NTA Hisbind Superflow resin (Novagen) pre-equilibrated in denaturing buffer (100 mM sodium phosphate, 10 mM Tris, 6 M Guanidine, 10 mM b-mercaptoethanol, pH 8.0). After 30 min. binding, resin was transferred to column support, and protein was refolded by a linear 12 hr. 125 mL gradient of denaturing to refolding buffer (100 mM sodium phosphate, 10 mM Tris, pH 8.0), followed by 60 mL wash at 1 mL/min. in refolding buffer. Protein was eluted from nickel affinity resin by 1 mL/min. 500 mM imidazole, 100 mM sodium phosphate pH 6.5; then dialyzed into 20 mM sodium phosphate pH 6.5 (362 L for 30 min.) and into water (362 L for 30 min., 164 L overnight). If observed, precipitate was removed by centrifugation at 100,0006g for 60 min. The nickel eluate was loaded on 2 mL pre-equilibrated (30 mL 10 mM sodium phosphate pH 6.5, 1 mL/min.) CM sepharose (Sigma, St. Louis, MO) at 0.5 mL/min., washed with 50 mL NaCl at 1 mL/min., and eluted with a gradient (300-650 mM NaCl, 0.5 mL/min. Sc ) were incubated with 3.5 mg purified E. coli recPrP-myc (wild-type or lacking polybasic domain) in 250 mL binding buffer (50 mM tris, 200 mM NaCl, 1% Triton X-100, 1% Tween-20, pH 7.5) for 1 hr. at 4uC with 10 r.p.m. end-over-end rotation. Concurrently, 16 mL 30 mg/mL Dynabeads Protein A (Invitrogen) was washed with 26500 mL phosphate-buffered saline (PBS), collected by a Magnetic Particle Separator (PureBiotech, Middlesex, NJ), and incubated with 3.6 mg 9E10 anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA) in 250 mL binding buffer for 30 min. at room temp. with 10 r.p.m. end-over-end rotation. Next, the solution of PrP Sc and PrP-myc was added to the bead-anti-myc complexes, and rotated for 1 hr. at 4uC. Following this incubation, beads were collected, and supernatant was aspirated. Beads were rinsed in 46500 mL wash buffer (50 mM tris, 200 mM NaCl, 0.05% Tween 20), and analyzed for bound PrP Sc . Signal intensities were quantified by densitometry with ImageGauge V4.22 (Fujifilm) in quant mode.
Expression and preparation of PrP from Chinese hamster ovary (CHO) cells
Sequences encoding wild-type and polybasic domain deletion mutant (DN = D23-28; DC-PBD = D100-109; DD-PBD = D23-28 D100-109) PrP were inserted in pcDNA5/FRT plasmids. These were used to express PrP from CHO cells, which was prepared as described previously [29] . For hamster experiments, homologous deletion mutants were used (D23-28, D101-110, or DD).
Reconstituted serial protein misfolding cyclic amplification (sPMCA) with CHO-expressed PrP
Reactions were prepared and carried out as described by Geoghegan et al. [29] . Briefly, CHO-expressed mouse PrP (wildtype or polybasic domain deletion mutant) was mixed with Prnp 0/0
Author Summary
Prions are unconventional infectious agents that cause fatal diseases in humans and other animals. Previous studies have suggested that prion infectivity depends upon the ability of a sample to change the shape of a normal brain protein called the prion protein (PrP) into a disease-associated shape. Other studies have identified a pair of positively charged domains within the structure of PrP that appear to be important for the interaction between the normal and disease-associated shapes of the prion protein. In this report, we show that the shape of normal PrP can change into the disease-associated form through a novel mechanism that does not involve positively charged domains. However, it appears that interaction through the positively charged domains is required to produce infectious prions efficiently. Our results show for the first time that the ability to change the shape of normal PrP into its disease-associated state is not the sole determinant of prion infectivity.
(Zurich) brain homogenate (2.5% final concentration). Ninety microliters of this reconstituted substrate was mixed with 10 mL seed. Reactions were initially seeded with 0.1% scrapie-infected brain homogenate (mouse strain RML) in PBS, with 10 mL of product used to seed the subsequent round. DC-PrP Sc seed was produced by 16 rounds of sPMCA (10 16 -fold dilution of original wild-type scrapie seed), containing ,1 original PrP Sc molecule [8] . Unseeded reactions were given 10 mL PBS as initial seed. For reactions lacking cofactor, buffer (PBS 1% Triton X-100) replaced Prnp 0/0 brain homogenate. Each PMCA round consisted of incubation at 37uC for 24 hr. with 20 sec. microplate horn sonication at 85% power every 30 min. One set of seeded samples was not subjected to PMCA (round 0), while another set was not subjected to protease digestion (2PK) to observe input PrP. For hamster sPMCA experiments, or Sc237 strain was used, CHO HaPrP was supplemented with 20 mg/mL synthetic poly(A) RNA (Sigma, St. Louis, MO), and PrP Sc was detected by immunoblot after 50 mg/mL digestion for 60 min.
sPMCA with brain homogenate
Brain homogenate sPMCA experiments were adapted from Castilla et al. [30] . 90 mL 10% CD-1 mouse brain (Biochemed, Winchester, VA) homogenate was prepared in PBS, 1% Triton X-100, 5 mM EDTA, Roche Complete mini protease inhibitor, then seeded with PrP Sc (10 mL of round 16 product). One round of PMCA consisted of 30 sec. 90% power microplate horn sonication pulses every 30 min. for 24 hr. at 37uC. 10 mL of each reaction product was transferred to fresh brain homogenate for the following round.
PrP
Sc detection
Mouse PrP Sc was detected by digestion with 25 mg/mL proteinase K (Roche, Indianapolis, IN) for 30 min. at 37uC and 750 r.p.m. shaking, polyacrylamide gel electrophoresis (PAGE), transfer to polyvinylidene fluoride (PVDF), and Western detection with anti-PrP and horseradish peroxidase-conjugated anti-mouse sheep IgG (GE Healthcare, Piscataway, NJ). Signals were detected by enhanced chemiluminescence (ECL) (SuperSignal West Femto Substrate, Pierce, Rockford, IL) and visualized by a Fuji (Fujifilm) LAS-3000 chemiluminescence documentation system. Hamster PrP Sc was detected with 50 mg/mL proteinase K for 60 min. Experiments detecting only wild-type PrP used 6D11 anti-PrP antibody. Because the central polybasic domain (C-PBD) forms part of the 6D11 epitope, and therefore DC PrP is not detected by 6D11 (data not shown), reconstituted sPMCA experiments utilized anti-PrP mAb 27/33.
Biological infectivity assay
RML PrP
Sc , propagated with CHO wild-type or DC-PrP C in vitro by sPMCA ( Figures 1B, S4 ) for at least 14 rounds, was diluted 1:10 in diluent (PBS+1 mg/mL BSA). DN-and DD-PrP Sc molecules, propagated from DC-PrP Sc ( Figure 2B ), were prepared in the same manner. By serial dilution, each inoculum contained 10 215 of the original seed, equivalent to less than one original PrP Sc molecule [8] . PrP Sc preparations (30 mL) were injected intracerebrally into female CD-1 mice aged 6 weeks (Charles River Laboratories, Wilmington, MA). For two samples (DC-PrP Sc and DD-PrP Sc ), end-point dilution bioassays were performed, in which 10-fold serial dilutions were inoculated to measure the amount of prion infectivity present in the original sample. As described previously [11] , animals were monitored daily for clinical signs of neurological dysfunction over the standard oneyear observation period. Animals showing terminal scrapie were sacrificed, and their brains were analyzed for PrP Sc (by 25 mg/mL protease digestion and immunoblot) and for spongiform degeneration (by hematoxylin & eosin histology) [11] . Random asymptomatic animals were sacrificed after one year, and their brains were likewise analyzed for PrP Sc and spongiform degeneration.
Ethics statement
All animals were handled in strict accordance with good animal practice, as defined by the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Dartmouth College Institutional Animal Care and Use Committee approved the animal work (assurance number A3259-01). Inoculations were performed under isoflurane anesthesia, and all efforts were made to minimize suffering.
Results
Interaction and propagation of wild-type PrP
Sc with PrP molecules lacking polybasic domains Studies using fragments of PrP identified N-terminal (23) (24) (25) (26) (27) (28) and central (100-109 in mouse) polybasic domains as potential binding sites for PrP Sc [14, 16] . To investigate the role of these domains in the context of full-length PrP C , we developed a novel magnet-based assay to examine direct interaction between PrP Sc and PrP C molecules with or without deletions of these polybasic regions. In this assay, PrP Sc was incubated with purified recombinant myc-tagged PrP, and then adherent molecules were pulled down by a-myc antibodies attached to Protein A magnetic beads. Substitution of a short myc epitope in place of the Cterminal glycophosphatidylinositol anchor of PrP C permitted specific capture. The assay specifically assesses PrP To test the function of PrP C polybasic domains in prion propagation, we performed sPMCA experiments with wild type and mutant PrP C substrate. These PrP C molecules, prepared from CHO cells transfected with wild-type or mutant Prnp DNA, were detergent-soluble ( Figure S3 in Supporting Information S1) and membrane-anchored ( Figure S4 in Supporting Information S1), indicative of proper folding and intracellular trafficking. In reconstituted, three-round sPMCA experiments with PrP C and Prnp 0/0 brain homogenate, PrP Sc propagated efficiently, converting the PrP C to protease-resistant autocatalytic PrP Sc molecules ( Figure 1B and S5 in Supporting Information S1). In contrast, PrP C molecules missing one (DN, DC) or both (DD) polybasic domains did not support efficient propagation, indicating that PrP C requires these domains to facilitate PrP Sc propagation. This result was also found with Sc237 hamster prions, as we observed no propagation of protease-resistant PrP with polybasic mutant hamster PrP C ( Figure S5 in Supporting Information S1). When we examined propagation in polybasic mutant substrates beyond three rounds, surprisingly, one mutant (DC) reproducibly produced PrP Sc molecules, typically between rounds 3-5 ( Figure 1B) . Further, these DC-PrP Sc molecules propagated robustly and indefinitely ( Figure S6 in Supporting Information S1), indicating capability of PrP C to support propagation despite absence of the central polybasic domain. Indeed, DC-PrP conversion was extremely efficient, with ,100% of substrate converted to PrP Sc , outpacing even wild-type PrP conversion ratios (,20% of substrate).
DC-PrP
Sc molecules appear to derive from the original wild-type PrP Sc seed, as unseeded reactions did not generate PrP Sc ( Figure 1B ).
Interaction range of DC-PrP Sc molecules
The unexpected generation of DC-PrP Sc molecules led us to conduct a series of experiments to assess the role of polybasic domains in DC-PrP Sc propagation. Using the magnetic myc-capture assay, we tested binding to various PrP substrates. In contrast to wildtype PrP Sc ,
DC-PrP
Sc reproducibly bound more strongly to DC-PrP (,50% of input) than to wild type PrP (,35% of input) (Figure 2A) . In addition to scrapie-seeded reactions, an unseeded reaction was performed with DC-PBD PrP substrate. One sample of each reaction was not subjected to protease digestion (2PK). All others were subjected to limited proteolysis with 25 mg/mL proteinase K. PrP was detected by immunoblot (anti-PrP 27/33 Figure 2B) . Moreover, the
Sc seed also propagated in DD-PrP C with robust conversion, indicating that presence of a polybasic domain is not an absolute requirement for PrP C to convert to a protease-resistant autocatalytic form. Indeed, all three types of DPBD-PrP Sc molecules propagated robustly, with stringent proteinase K digestion (25 mg/mL) revealing a protease-resistant core with a ,7 kDa molecular weight shift.
Cofactor dependence and seeding specificity of PrP
Sc molecules lacking polybasic domains
Infectious wild-type PrP Sc molecules depend on accessory cofactor molecules for propagation [11, 12, 31] . We tested whether polybasic domain mutant PrP Sc molecules exhibit this characteristic by performing parallel sPMCA reactions, omitting the supplemental Prnp 0/0 brain homogenate from one set ( Figure 3 ).
All three PrP
Sc mutants (DC, DN, and DD) failed to propagate in the absence of Prnp 0/0 brain homogenate, pointing to a cofactordependent propagation mechanism. The signals seen in initial rounds of cofactor-negative propagation are likely due to the presence of residual Prnp 0/0 brain homogenate carried over from the PrP Sc seed mixture. By the third round of sPMCA in cofactorfree substrate, no PrP Sc molecules were detected. 
Infectious PrP
Sc seeds propagation in wild-type brain homogenate [32, 33] to the extent that successful sPMCA propagation is considered potentially diagnostic for prion infectivity [9] . We tested if DPBD-PrP Sc molecules could seed propagation in wildtype brain homogenate (Figure 4) . Like wild-type PrP Sc , all three PrP Sc polybasic mutants (DC, DN, and DD) seeded serial propagation with success. Each of these reactions displayed positive conversion signals in round 1, suggesting a high amount of prion infectivity [34] . Interestingly, the PrP Sc molecules that formed were predominantly diglycosylated, whereas PrP Sc molecules formed from wild-type seeds displayed the three glycoforms in equivalent amounts. It has been shown that the ability to produce different PrPSc glycoforms is not due to preferential interaction, but rather inherent conformation [35] . This study found that mouse RML prions only require unglycosylated PrP C for propagation, and that glycosylated forms of PrP Sc can be made in its presence. This suggests that the observed glycosylation pattern described here may be caused by a different fold in polybasic mutant PrP Sc . Thus, all three PBD mutant PrP Sc molecules share the hallmark biochemical characteristics of infectious wild-type PrP Sc molecules [11] : (1) a highly protease-resistant core, (2) cofactor-dependent propagation, and (3) the ability to seed wild-type brain homogenate sPMCA reactions.
Infectivity of polybasic mutant PrP Sc molecules
We tested whether mutant PrP Sc molecules, generated in vitro from CHO-expressed PrP, are infectious to animals. Following sPMCA propagation sufficient to dilute out original seeds, wildtype and mutant (DC, DN, and DD) PrP Sc molecules were inoculated intracerebrally into wild-type mice. Wild-type CHO PrP Sc contains significant infectivity, causing scrapie disease in all animals with an incubation period comparable to RML prions propagated in vitro in brain homogenate [36] (Table 1) . Affected animals displayed accumulation of protease-resistant prion protein and significant histopathological spongiform degeneration ( Figure 5 ), as we previously reported for hamster prions propagated in vitro in wild-type CHO-expressed hamster PrP [29] . Animals inoculated with wild-type CHO PrP Sc also showed robust levels of protease-resistant PrP Sc on Western blot. In contrast to wild-type, polybasic mutant PrP Sc molecules show diminished in vivo infectivity.
DC-PrP
Sc caused scrapie disease only in a fraction of animals, including those receiving the most concentrated inocula, with an incubation time 2.5-fold greater than animals inoculated with wild-type PrP Sc . DC-PrP Sc -inoculated diseased animals showed mild vacuolation (Figures 5B and S7 in Supporting Information S1) and displayed low levels of PrP Sc on Western blot, with diglycosylated molecules most abundant. Such a glycoform ratio contrasts with the even distribution of glycoforms in animals inoculated with wild-type PrP Sc (Figures 5A and S8 in Supporting Information S1), also seen with in vitro propagation (Figure 4 ). Both wild-type and DC-PrP Sc induced scrapie illness characterized neurologically by lethargy and ataxia. DN-PrP Sc molecules induced scrapie illness in a single animal, following a 564-day incubation period (Figure S9 in Supporting Information S1), with other such inoculated animals showing no scrapie illness ( Figure 5 ). Due to the sudden nature of some deaths, we did not obtain tissue from all animals, but brain samples from many nonscrapie deaths were obtained as indicated in Table 1 . DD-PrP Sc molecules did not induce scrapie illness, as gauged by clinical observation and lack of protease-resistant PrP or histopathological change in animals sacrificed over one year after inoculation ( Figure 5 ). Thus, while polybasic deletion mutant PrP Sc molecules recapitulated in vitro many characteristics of infectious PrP Sc molecules, they displayed low specific infectivity in wild-type mice.
Discussion
In this study, we have engineered polybasic domain deficient PrP Sc molecules that efficiently interact with and catalyze the conversion of an expanded range of PrP C substrates, including native PrP C in wild-type mouse brain homogenate. Remarkably, despite possessing the biochemical characteristics and in vitro 
Requirement of PrP
C polybasic domains for propagation of wild-type PrP Sc
Studies of PrP fragments have indicated that polybasic domains can interact with PrP
Sc [14, 16] . To investigate both prion binding and conversion in the context of the entire PrP molecule, we designed mutant prion proteins lacking one or both polybasic domains, which were detergent-soluble and properly trafficked, as determined by PI-PLC release. Using a novel magnetic capture assay, we found that both PrP C polybasic domains were required for optimal PrP Sc binding. In reconstituted sPMCA experiments with PrP expressed and prepared from CHO cells, deletion of either or both polybasic domains of substrate PrP C prevented efficient propagation of wild-type PrP Sc . As mutants lacking either domain did not efficiently bind or propagate wild-type PrP Sc , both PrP C polybasic domains appear required to contact PrP Sc for efficient propagation of wild-type prions.
Work using N2a cells co-expressing wild-type and mutant PrP suggested that the N-terminal polybasic domain may not play a role in conversion [27] . However, the presence of endogenous wild-type PrP C may have provided conditions that facilitated conversion of the weaker-binding mutant PrP substrate. The results presented in this paper, using mutant substrate alone to test binding and propagation, suggest that the PrP C N-terminal polybasic domain indeed participates in wild-type PrP Sc binding and propagation.
Delayed conversion of PrP lacking polybasic domains
When sPMCA reactions seeded with wild-type prions were carried out to 3-5 rounds, DC-PrP C substrate molecules converted to a form resistant to protease digestion under stringent conditions (25 mg/mL proteinase K at 37uC). After protease digestion, this form displayed a classical shift in molecular weight of ,7 kDa. This form was also autocatalytic, continuing to propagate robustly (,100% conversion) and indefinitely in DC-PrP C substrate. In seeking to understand the surprising kinetics of the initial conversion event, which occurred after four rounds and 10 24 dilution of the original seed, we found that unseeded control reactions did not Sc molecules seeding wild-type brain homogenate sPMCA reactions. In vitro-generated DC-PBD, DN-PBD, and DD-PBD PrP Sc molecules were propagated by sPMCA for three rounds with wild-type mouse brain homogenate, containing wild-type PrP C substrate. Control reactions seeded with wild-type native RML prions and unseeded reactions were also tested. One sample of each reaction was not subjected to protease digestion (2PK), while all others were digested with 25 mg/mL proteinase K. PrP was detected by immunoblot (anti-PrP 6D11). doi:10.1371/journal.ppat.1002128.g004 generate the mutant PrP Sc product. Thus, DC-PrP Sc did not arise de novo [11] , but may have emerged from amplification of a few molecules of a minority conformation present in the original PrP Sc seed. Such an event is consistent with recent reports of multiple prion strains emerging from a single ''pure'' source [37, 38] , and 4-5 serial amplification rounds are required to detect PrP Sc conformers at very low concentrations [34] .
Expanded substrate range and increased converting efficiency of DC-PrP
Sc
Once formed, the novel DC-PrP Sc molecules bound to and propagated in DN-PrP C and DD-PrP C substrates, forming new PrP Sc molecules lacking either one or both polybasic domains. Thus, in contrast to wild-type PrP Sc , DC-PrP Sc is universally catalytic in polybasic mutant PrP C , exhibiting an expanded substrate range that points to an alternative docking mechanism during propagation. Each of the DPBD PrP Sc species propagated robustly, including even the mutant lacking both polybasic domains (DD). While wild-type PrP Sc propagates by binding to substrate polybasic domains, DPBD mutant PrP Sc molecules appear to utilize a different mechanism to bind PrP C , as outlined by the model in Figure 6 . This indicates that prion docking, and perhaps other events in conversion, do not necessarily follow a rigidly conserved mechanism. In contrast, self-replicating fungal prions appear to utilize a stereotypic mechanism requiring glutamine/asparagine repeats [39] .
The expanded interaction range of mutant PrP Sc molecules could be explained by the exposure of a neoepitope on mutant PrP Sc ( Figure 6 ). If DPBD mutant PrP Sc molecules propagate from a minority constituent conformer within wild-type PrP Sc , the putative neoepitope may also be present on these minority seed molecules.
Mechanisms of PrP
Sc docking may also vary between different natural prion strains. Further studies are required to assess bindingsite heterogeneity of PrP Sc -PrP C interactions, including identification of specific docking sites used by DD-PBD molecules.
We also observed that 100% attack rate (scrapie incubation time = 180611 days). In contrast, despite exhibiting the in vitro hallmarks of wild-type infectious PrP Sc as described above, mutant DC-PrP Sc and DNPrP Sc molecules showed low infectivity in vivo (#3000 LD 50 units/ mL and ,300 LD 50 units/mL, respectively), and DD-PrP Sc showed no infectivity. Some inoculum-host PrP sequence Nterminal differences can mildly prolong scrapie incubation time, but these did not alter attack rates [46, 47] , and much larger Nterminal PrP Sc deletions than the DN-PrP Sc that we report here did not significantly affect incubation time or attack rate in wildtype animals [23] . For example, protease-digested PrP Sc yields PrP27-30, which is highly infectious to wild-type animals despite lacking amino acids 23-88 [48, 49] . Given that DPBD PrP Sc molecules drive robust propagation in vitro in wild-type brain homogenate sPMCA, their diminished biological infectivity was highly unexpected, and represents dissociation between in vitro catalysis and in vivo infectivity, most notably for DN-PBD and DD-PBD PrP Sc . To our knowledge, this report is the first demonstration of absent or minimal infectivity in samples that successfully seed propagation of wild-type brain homogenate during sPMCA, suggesting that the normal route of PrP C /PrP
Sc interaction through polybasic domains may be required for generating infectious prions. Why might appropriate PBD-mediated interaction be required for infectivity? One possibility is that PBDdeficient PrP Sc molecules may be more susceptible to existing host mechanisms for prion clearance [50, 51, 52, 53] , perhaps by exposure of a neoepitope on PrP
Sc that serves as a clearance signal. If this explanation were correct, then all three PBDdeficient PrP Sc molecules must be preferential targets for the clearance mechanism.
A more plausible explanation is that the non-PBD mediated interaction mechanisms used by DPBD-PrP Sc molecules to propagate in vitro lead to the production of alternative PrP Sc conformations that are intrinsically non-infectious or have reduced infectivity. Consistent with this explanation, we observed different PrP Sc glycosylation patterns in animals inoculated with DC-PrP Sc compared to animals inoculated with wild-type PrP Sc . Such a distinction could be caused by an altered ability of mutant PrP Sc to interact with non-PrP host molecules during in vivo propagation. For example, the in vitro detergent micelle environment differs from the membrane environments where propagation occurs in vivo. On the other hand, high titers of strain-preserved prion infectivity are propagated in vitro in detergent micelles [8, 11, 32] , suggesting that in vitro propagation recapitulates native events fairly well.
Finally, it should be emphasized that although mutant PrP Sc molecules were used in this study to uncover the dissociation between seeding ability and infectivity, the results are directly relevant to the mechanisms responsible for forming naturally occurring prions because normal wild type brain homogenates and normal wild type mice were used in sPMCA seeding assays and in vivo bioassays, respectively. The contrast between highly infectious wild type PrP Sc and minimally infectious DPBD-PrP Sc molecules provides a novel paradigm that can be used to determine the specific structural basis of prion infectivity. 
